Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 266

1.

Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model.

Nguyen F, Alferiev I, Guan P, Guerrero DT, Kolla V, Moorthy GS, Chorny M, Brodeur GM.

Clin Cancer Res. 2018 Mar 7. doi: 10.1158/1078-0432.CCR-17-3811. [Epub ahead of print]

PMID:
29514842
2.

Spontaneous regression of neuroblastoma.

Brodeur GM.

Cell Tissue Res. 2018 Jan 5. doi: 10.1007/s00441-017-2761-2. [Epub ahead of print] Review.

PMID:
29305654
3.

The Future of Surveillance in the Context of Cancer Predisposition: Through the Murky Looking Glass.

Malkin D, Nichols KE, Schiffman JD, Plon SE, Brodeur GM.

Clin Cancer Res. 2017 Nov 1;23(21):e133-e137. doi: 10.1158/1078-0432.CCR-17-2026.

PMID:
29093018
4.

Retinoblastoma and Neuroblastoma Predisposition and Surveillance.

Kamihara J, Bourdeaut F, Foulkes WD, Molenaar JJ, Mossé YP, Nakagawara A, Parareda A, Scollon SR, Schneider KW, Skalet AH, States LJ, Walsh MF, Diller LR, Brodeur GM.

Clin Cancer Res. 2017 Jul 1;23(13):e98-e106. doi: 10.1158/1078-0432.CCR-17-0652. Review.

PMID:
28674118
5.

Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome.

Foulkes WD, Kamihara J, Evans DGR, Brugières L, Bourdeaut F, Molenaar JJ, Walsh MF, Brodeur GM, Diller L.

Clin Cancer Res. 2017 Jun 15;23(12):e62-e67. doi: 10.1158/1078-0432.CCR-17-0595. Review.

PMID:
28620006
6.

Pediatric Cancer Predisposition and Surveillance: An Overview, and a Tribute to Alfred G. Knudson Jr.

Brodeur GM, Nichols KE, Plon SE, Schiffman JD, Malkin D.

Clin Cancer Res. 2017 Jun 1;23(11):e1-e5. doi: 10.1158/1078-0432.CCR-17-0702. Review.

PMID:
28572261
7.

Management of adrenal masses in patients with Beckwith-Wiedemann syndrome.

MacFarland SP, Mostoufi-Moab S, Zelley K, Mattei PA, States LJ, Bhatti TR, Duffy KA, Brodeur GM, Kalish JM.

Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26432. Epub 2017 Jan 9. Review.

PMID:
28066990
8.

The "neuro" of neuroblastoma: Neuroblastoma as a neurodevelopmental disorder.

Ratner N, Brodeur GM, Dale RC, Schor NF.

Ann Neurol. 2016 Jul;80(1):13-23. doi: 10.1002/ana.24659. Epub 2016 Apr 30. Review.

9.

Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas.

Naraparaju K, Kolla V, Zhuang T, Higashi M, Iyer R, Kolla S, Okawa ER, Blobel GA, Brodeur GM.

Oncotarget. 2016 Mar 29;7(13):15977-85. doi: 10.18632/oncotarget.7434.

10.

Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.

Iyer R, Wehrmann L, Golden RL, Naraparaju K, Croucher JL, MacFarland SP, Guan P, Kolla V, Wei G, Cam N, Li G, Hornby Z, Brodeur GM.

Cancer Lett. 2016 Mar 28;372(2):179-86. doi: 10.1016/j.canlet.2016.01.018. Epub 2016 Jan 18.

11.

Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.

Thompson D, Vo KT, London WB, Fischer M, Ambros PF, Nakagawara A, Brodeur GM, Matthay KK, DuBois SG.

Cancer. 2016 Mar 15;122(6):935-45. doi: 10.1002/cncr.29848. Epub 2015 Dec 28.

12.

Retinoic acid-induced CHD5 upregulation and neuronal differentiation of neuroblastoma.

Higashi M, Kolla V, Iyer R, Naraparaju K, Zhuang T, Kolla S, Brodeur GM.

Mol Cancer. 2015 Aug 7;14:150. doi: 10.1186/s12943-015-0425-y.

13.

The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex.

Kolla V, Naraparaju K, Zhuang T, Higashi M, Kolla S, Blobel GA, Brodeur GM.

Biochem J. 2015 Jun 1;468(2):345-52. doi: 10.1042/BJ20150030.

14.

Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy.

Alferiev IS, Iyer R, Croucher JL, Adamo RF, Zhang K, Mangino JL, Kolla V, Fishbein I, Brodeur GM, Levy RJ, Chorny M.

Biomaterials. 2015 May;51:22-9. doi: 10.1016/j.biomaterials.2015.01.075. Epub 2015 Feb 16.

15.

Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.

Iyer R, Croucher JL, Chorny M, Mangino JL, Alferiev IS, Levy RJ, Kolla V, Brodeur GM.

Cancer Lett. 2015 May 1;360(2):205-12. doi: 10.1016/j.canlet.2015.02.011. Epub 2015 Feb 12.

16.

TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.

Croucher JL, Iyer R, Li N, Molteni V, Loren J, Gordon WP, Tuntland T, Liu B, Brodeur GM.

Cancer Chemother Pharmacol. 2015 Jan;75(1):131-41. doi: 10.1007/s00280-014-2627-1. Epub 2014 Nov 14.

17.

Mechanisms of neuroblastoma regression.

Brodeur GM, Bagatell R.

Nat Rev Clin Oncol. 2014 Dec;11(12):704-13. doi: 10.1038/nrclinonc.2014.168. Epub 2014 Oct 21. Review.

18.

Mutations in NTRK3 suggest a novel signaling pathway in human congenital heart disease.

Werner P, Paluru P, Simpson AM, Latney B, Iyer R, Brodeur GM, Goldmuntz E.

Hum Mutat. 2014 Dec;35(12):1459-68. doi: 10.1002/humu.22688. Epub 2014 Nov 7.

19.

Rotary bioreactor culture can discern specific behavior phenotypes in Trk-null and Trk-expressing neuroblastoma cell lines.

Redden RA, Iyer R, Brodeur GM, Doolin EJ.

In Vitro Cell Dev Biol Anim. 2014 Mar;50(3):188-93. doi: 10.1007/s11626-013-9716-z. Epub 2014 Jan 30.

20.

Role of CHD5 in human cancers: 10 years later.

Kolla V, Zhuang T, Higashi M, Naraparaju K, Brodeur GM.

Cancer Res. 2014 Feb 1;74(3):652-8. doi: 10.1158/0008-5472.CAN-13-3056. Epub 2014 Jan 13. Review.

21.

Therapeutic targets for neuroblastomas.

Brodeur GM, Iyer R, Croucher JL, Zhuang T, Higashi M, Kolla V.

Expert Opin Ther Targets. 2014 Mar;18(3):277-92. doi: 10.1517/14728222.2014.867946. Epub 2014 Jan 6. Review.

22.

CHD5 is required for spermiogenesis and chromatin condensation.

Zhuang T, Hess RA, Kolla V, Higashi M, Raabe TD, Brodeur GM.

Mech Dev. 2014 Feb;131:35-46. doi: 10.1016/j.mod.2013.10.005. Epub 2013 Nov 16.

23.

Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stages.

Fatemi M, Paul TA, Brodeur GM, Shokrani B, Brim H, Ashktorab H.

Cancer. 2014 Jan 15;120(2):172-80. doi: 10.1002/cncr.28316. Epub 2013 Nov 14.

24.

Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project.

Schleiermacher G, Mosseri V, London WB, Maris JM, Brodeur GM, Attiyeh E, Haber M, Khan J, Nakagawara A, Speleman F, Noguera R, Tonini GP, Fischer M, Ambros I, Monclair T, Matthay KK, Ambros P, Cohn SL, Pearson AD.

Br J Cancer. 2012 Oct 9;107(8):1418-22. doi: 10.1038/bjc.2012.375. Epub 2012 Sep 13.

25.

AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.

Iyer R, Varela CR, Minturn JE, Ho R, Simpson AM, Light JE, Evans AE, Zhao H, Thress K, Brown JL, Brodeur GM.

Cancer Chemother Pharmacol. 2012 Sep;70(3):477-86. doi: 10.1007/s00280-012-1879-x. Epub 2012 May 24.

26.

Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641.

Strother DR, London WB, Schmidt ML, Brodeur GM, Shimada H, Thorner P, Collins MH, Tagge E, Adkins S, Reynolds CP, Murray K, Lavey RS, Matthay KK, Castleberry R, Maris JM, Cohn SL.

J Clin Oncol. 2012 May 20;30(15):1842-8. doi: 10.1200/JCO.2011.37.9990. Epub 2012 Apr 23.

27.

A three-gene expression signature model for risk stratification of patients with neuroblastoma.

Garcia I, Mayol G, Ríos J, Domenech G, Cheung NK, Oberthuer A, Fischer M, Maris JM, Brodeur GM, Hero B, Rodríguez E, Suñol M, Galvan P, de Torres C, Mora J, Lavarino C.

Clin Cancer Res. 2012 Apr 1;18(7):2012-23. doi: 10.1158/1078-0432.CCR-11-2483. Epub 2012 Feb 10.

28.

Mechanisms of CHD5 Inactivation in neuroblastomas.

Koyama H, Zhuang T, Light JE, Kolla V, Higashi M, McGrady PW, London WB, Brodeur GM.

Clin Cancer Res. 2012 Mar 15;18(6):1588-97. doi: 10.1158/1078-0432.CCR-11-2644. Epub 2012 Jan 31.

29.

Clinical significance of NTRK family gene expression in neuroblastomas.

Light JE, Koyama H, Minturn JE, Ho R, Simpson AM, Iyer R, Mangino JL, Kolla V, London WB, Brodeur GM.

Pediatr Blood Cancer. 2012 Aug;59(2):226-32. doi: 10.1002/pbc.23343. Epub 2011 Oct 11.

30.

Knowing your ABCCs: novel functions of ABCC transporters.

Brodeur GM.

J Natl Cancer Inst. 2011 Aug 17;103(16):1207-8. doi: 10.1093/jnci/djr277. Epub 2011 Jul 28. No abstract available.

31.

Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma.

Norris RE, Minturn JE, Brodeur GM, Maris JM, Adamson PC.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1469-75. doi: 10.1007/s00280-011-1623-y. Epub 2011 Apr 12.

32.

The effect of P75 on Trk receptors in neuroblastomas.

Ho R, Minturn JE, Simpson AM, Iyer R, Light JE, Evans AE, Brodeur GM.

Cancer Lett. 2011 Jun 1;305(1):76-85. doi: 10.1016/j.canlet.2011.02.029. Epub 2011 Mar 17.

33.

Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study.

Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, Groshen S, Hellriegel ET, Bensen-Kennedy D, Matthay KK, Brodeur GM, Maris JM.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1057-65. doi: 10.1007/s00280-011-1581-4. Epub 2011 Feb 22.

34.

Getting into the AKT.

Brodeur GM.

J Natl Cancer Inst. 2010 Jun 2;102(11):747-9. doi: 10.1093/jnci/djq171. Epub 2010 May 12. No abstract available.

PMID:
20463308
35.

Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma.

Iyer R, Evans AE, Qi X, Ho R, Minturn JE, Zhao H, Balamuth N, Maris JM, Brodeur GM.

Clin Cancer Res. 2010 Mar 1;16(5):1478-85. doi: 10.1158/1078-0432.CCR-09-1531. Epub 2010 Feb 23.

36.

Trk receptor expression and inhibition in neuroblastomas.

Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, Light JE, Kolla V, Evans AE.

Clin Cancer Res. 2009 May 15;15(10):3244-50. doi: 10.1158/1078-0432.CCR-08-1815. Epub 2009 May 5. Review.

37.

International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.

Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, London WB, Cohn SL, Pearson AD, Maris JM.

Br J Cancer. 2009 May 5;100(9):1471-82. doi: 10.1038/sj.bjc.6605014.

38.

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK; INRG Task Force.

J Clin Oncol. 2009 Jan 10;27(2):289-97. doi: 10.1200/JCO.2008.16.6785. Epub 2008 Dec 1.

39.

The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.

Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD; INRG Task Force.

J Clin Oncol. 2009 Jan 10;27(2):298-303. doi: 10.1200/JCO.2008.16.6876. Epub 2008 Dec 1.

40.

Identification of ALK as a major familial neuroblastoma predisposition gene.

Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM.

Nature. 2008 Oct 16;455(7215):930-5. doi: 10.1038/nature07261. Epub 2008 Aug 24.

41.

CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas.

Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V, Kim J, Zhao H, Pawel BR, London WB, Maris JM, White PS, Brodeur GM.

J Natl Cancer Inst. 2008 Jul 2;100(13):940-9. doi: 10.1093/jnci/djn176. Epub 2008 Jun 24.

42.

A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene.

Cole KA, Attiyeh EF, Mosse YP, Laquaglia MJ, Diskin SJ, Brodeur GM, Maris JM.

Mol Cancer Res. 2008 May;6(5):735-42. doi: 10.1158/1541-7786.MCR-07-2102.

43.

Molecular analysis of gene amplification in tumors.

Wasson JC, Brodeur GM.

Curr Protoc Hum Genet. 2001 May;Chapter 10:Unit 10.5. doi: 10.1002/0471142905.hg1005s02.

PMID:
18428242
44.

Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.

Schneiderman J, London WB, Brodeur GM, Castleberry RP, Look AT, Cohn SL.

J Clin Oncol. 2008 Feb 20;26(6):913-8. doi: 10.1200/JCO.2007.13.9493.

PMID:
18281664
45.

Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas.

Okawa ER, Gotoh T, Manne J, Igarashi J, Fujita T, Silverman KA, Xhao H, Mosse YP, White PS, Brodeur GM.

Oncogene. 2008 Jan 31;27(6):803-10. Epub 2007 Jul 30.

PMID:
17667943
46.

Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.

Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, Seiser E, Jagannathan J, Shusterman S, Bansal M, Khazi D, Winter C, Okawa E, Grant G, Cnaan A, Zhao H, Cheung NK, Gerald W, London W, Matthay KK, Brodeur GM, Maris JM.

Cancer Res. 2006 Jun 15;66(12):6050-62.

47.

Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.

Bagatell R, Rumcheva P, London WB, Cohn SL, Look AT, Brodeur GM, Frantz C, Joshi V, Thorner P, Rao PV, Castleberry R, Bowman LC.

J Clin Oncol. 2005 Dec 1;23(34):8819-27.

PMID:
16314642
48.

Chromosome 1p and 11q deletions and outcome in neuroblastoma.

Attiyeh EF, London WB, Mossé YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, Brodeur GM, Cohn SL, Matthay KK, Maris JM; Children's Oncology Group.

N Engl J Med. 2005 Nov 24;353(21):2243-53.

49.

Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor.

Ho R, Minturn JE, Hishiki T, Zhao H, Wang Q, Cnaan A, Maris J, Evans AE, Brodeur GM.

Cancer Res. 2005 Nov 1;65(21):9868-75.

50.

Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.

George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, Brodeur GM, Castleberry RP, Look AT.

J Clin Oncol. 2005 Sep 20;23(27):6466-73. Epub 2005 Aug 22.

PMID:
16116152

Supplemental Content

Loading ...
Support Center